$XBP
XBP Europe Holdings Inc Stock $xbp

$xbp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023039788 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit	$9.460M
YoY Change
Gross Profit Margin
Selling, General & Admin	$609.6K	$413.8K
YoY Change	47.31%	300.18%
% of Gross Profit	6.44%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$910.0K
YoY Change
% of Gross Profit	9.62%
Operating Expenses	$609.6K	$413.8K
YoY Change	47.31%	300.18%
Operating Profit	-$609.6K	-$413.8K
YoY Change	47.31%
Interest Expense	$85.15K	$53.77K
YoY Change	58.36%	-102.89%
% of Operating Profit
Other Income/Expense, Net	$100.0K	$3.772M
YoY Change	-97.35%	2635.23%
Pretax Income	-$1.594M	$3.412M
YoY Change	-146.7%	-287.18%
Income Tax	$100.0K
% Of Pretax Income
Net Earnings	-$1.594M	$3.412M
YoY Change	-146.7%	-287.17%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11
Diluted Earnings Per Share	-$0.17	$110.3K
COMMON SHARES
Basic Shares Outstanding	21.80M
Diluted Shares Outstanding	21.80M

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.00K	$25.00K
YoY Change	0.0%	0.0%
Cash & Equivalents	$25.00K	$25.00K
Short-Term Investments
Other Short-Term Assets	$460.6K	$44.63K
YoY Change	932.0%	-95.32%
Inventory
Prepaid Expenses	$460.6K
Receivables
Other Receivables
Total Short-Term Assets	$485.6K	$69.63K
YoY Change	597.37%	-92.88%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$15.47M	$225.6M
YoY Change	-93.14%	-9.75%
Other Assets		$570.8K
YoY Change
Total Long-Term Assets	$15.47M	$226.2M
YoY Change	-93.16%	-9.52%
TOTAL ASSETS
Total Short-Term Assets	$485.6K	$69.63K
Total Long-Term Assets	$15.47M	$226.2M
Total Assets	$15.96M	$226.3M
YoY Change	-92.95%	-9.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$1.340M	$815.5K
YoY Change	64.34%	3744.88%
Deferred Revenue
YoY Change
Short-Term Debt	$9.121M	$5.452M
YoY Change	67.28%	972.85%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.60M	$6.889M
YoY Change	53.92%	1141.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.434M	$4.066M
YoY Change	-15.56%	-59.49%
Total Long-Term Liabilities	$3.434M	$4.066M
YoY Change	-15.56%	-59.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.60M	$6.889M
Total Long-Term Liabilities	$3.434M	$4.066M
Total Liabilities	$14.04M	$10.95M
YoY Change	28.13%	3.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$13.90M
YoY Change
Common Stock	$554.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$13.45M	-$10.31M
YoY Change
Total Liabilities & Shareholders Equity	$15.96M	$226.3M
YoY Change	-92.95%	-9.85%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.594M	$3.412M
YoY Change	-146.7%	-287.17%
Depreciation, Depletion And Amortization	$910.0K
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures	$622.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$16.32M	$24.40M
YoY Change	-33.11%	-109.76%
Cash From Investing Activities	$16.32M	$24.40M
YoY Change	-33.11%	-109.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$16.34M	-24.40M
YoY Change	-33.04%	-109.76%
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities	$16.32M	24.40M
Cash From Financing Activities	-$16.34M	-24.40M
Net Change In Cash	-$16.15K	$0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures	$622.0K
Free Cash Flow	-$622.0K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40206
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2002883
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2023Q1	dei	City Area Code CityAreaCode	(212)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	938-5000
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q1	us-gaap	Cash Cash	25000	usd
CY2022Q4	us-gaap	Cash Cash	41154	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	460576	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	210241	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	485576	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	251395	usd
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	15469492	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31445874	usd
CY2023Q1	us-gaap	Assets Assets	15955068	usd
CY2022Q4	us-gaap	Assets Assets	31697269	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1340161	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1189676	usd
CY2023Q1	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	259658	usd
CY2022Q1	cffe	Change In Fair Value Of Forward Purchase Securities Liability ChangeInFairValueOfForwardPurchaseSecuritiesLiability	-47329	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1593525	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3412413	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11615460	usd
CY2023Q1	cffe	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	9120545	usd
CY2022Q4	cffe	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	8200162	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	80000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	70065	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	62406	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10603112	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9459903	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	669787	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	178780	usd
CY2023Q1	cffe	Forward Purchase Securities Liability ForwardPurchaseSecuritiesLiability	2763872	usd
CY2022Q4	cffe	Forward Purchase Securities Liability ForwardPurchaseSecuritiesLiability	2504214	usd
CY2023Q1	us-gaap	Liabilities Liabilities	14036771	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12142897	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	15369492	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	31169832	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	54	usd
CY2022Q4	cffe	Common Stock Value One CommonStockValueOne	625	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	452382	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	694592	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13904256	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12310731	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-13451195	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11615460	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15955068	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31697269	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	499562	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	371254	usd
CY2023Q1	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	30000	usd
CY2022Q1	cffe	Related Party Transaction Selling General And Administrative Expenses From Transaction With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionWithRelatedParty	30000	usd
CY2023Q1	us-gaap	Taxes Other TaxesOther	80000	usd
CY2022Q1	us-gaap	Taxes Other TaxesOther	12534	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-609562	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-413788	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	344809	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	6440	usd
CY2023Q1	cffe	Interest Expense Mandatorily Redeemable Securities InterestExpenseMandatorilyRedeemableSecurities	578107	usd
CY2022Q1	us-gaap	Other Income OtherIncome	579294	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	491007	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3193138	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	242210	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1593525	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-13451195	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9352134	usd
CY2022Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4424015	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	49411	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3412413	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-10314325	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1593525	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3412413	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	49411	usd
CY2023Q1	cffe	General And Administrative Expenses Paid By Related Party GeneralAndAdministrativeExpensesPaidByRelatedParty	184304	usd
CY2022Q1	cffe	General And Administrative Expenses Paid By Related Party GeneralAndAdministrativeExpensesPaidByRelatedParty	258373	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	344809	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6440	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	578107	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	491007	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3193138	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	259658	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-47329	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-264838	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-210338	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	150485	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-533628	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	9935	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-150000	usd
CY2023Q1	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	57464	usd
CY2022Q1	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	4424015	usd
CY2023Q1	cffe	Proceeds From Trust Account To Pay Franchise Taxes ProceedsFromTrustAccountToPayFranchiseTaxes	150115	usd
CY2022Q1	cffe	Proceeds From Trust Account To Pay Franchise Taxes ProceedsFromTrustAccountToPayFranchiseTaxes	24113	usd
CY2023Q1	cffe	Proceeds From Trust Account To Redeem Public Shares ProceedsFromTrustAccountToRedeemPublicShares	16228539	usd
CY2022Q1	cffe	Proceeds From Trust Account To Redeem Public Shares ProceedsFromTrustAccountToRedeemPublicShares	28799270	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16321190	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24399368	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	590672	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4717775	usd
CY2023Q1	cffe	Redemption Paymentfor Public Shares RedemptionPaymentforPublicShares	16290945	usd
CY2022Q1	cffe	Redemption Paymentfor Public Shares RedemptionPaymentforPublicShares	28799270	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	699477	usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	317873	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	62406	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-16337344	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24399368	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16154	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41154	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25000	usd
CY2023Q1	cffe	Prepaid Expenses Paid With Payables To Related Party PrepaidExpensesPaidWithPayablesToRelatedParty	515173	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	4900000	usd
CY2023Q1	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	400000	usd
CY2023Q1	cffe	Redeem Public Share Percentage RedeemPublicSharePercentage	1	pure
CY2022Q3	cffe	Aggregate Amount AggregateAmount	976832	usd
CY2022Q3	cffe	Public Share Per Share PublicSharePerShare	0.33
CY2023Q1	cffe	Aggregate Amount AggregateAmount	344781	usd
CY2023Q1	cffe	Extension Loan ExtensionLoan	57464	usd
CY2023Q1	cffe	Public Share Per Share PublicSharePerShare	0.04
CY2023Q1	cffe	Public Share Per Share PublicSharePerShare	10.69
CY2023Q1	cffe	Trust Account TrustAccount	16290945	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41200	usd
CY2023Q1	cffe	Working Capital WorkingCapital	10118000	usd
CY2022Q4	cffe	Working Capital WorkingCapital	9209000	usd
CY2023Q1	cffe	Sponsor Exchange SponsorExchange	25000	usd
CY2023Q1	us-gaap	Sponsor Fees SponsorFees	79000	usd
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	1750000	usd
CY2022Q2	cffe	Working Capital Loan WorkingCapitalLoan	1000000	usd
CY2022Q4	cffe	Working Capital Loan WorkingCapitalLoan	750000	usd
CY2023Q2	cffe	Extensions Loan ExtensionsLoan	344781	usd
CY2023Q1	cffe	Working Capital Loan WorkingCapitalLoan	500000	usd
CY2023Q1	cffe	Face Amounts Loan FaceAmountsLoan	9121000	usd
CY2022Q4	cffe	Face Amounts Loan FaceAmountsLoan	8500000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	100000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these unaudited condensed consolidated financial statements is the determination of the fair value of the warrant liability, FPS liability and sponsor loans liability. Such estimates may be subject to change as more current information becomes available and accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the Federal Deposit Insurance Corporation maximum coverage limit of $250,000, and cash equivalents held in the Trust Account. Any loss incurred or lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows. For the three months ended March 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	248396	usd
CY2023Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021Q1	cffe	Issued And Outstanding Shares Percentage IssuedAndOutstandingSharesPercentage	0.20	pure
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29000	usd
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	On March 11, 2021, the Company effected a 1.1-for-1 stock split.
CY2021Q1	cffe	Initial Shareholders Holding Percentage InitialShareholdersHoldingPercentage	0.20	pure
CY2023Q1	us-gaap	Shares Outstanding SharesOutstanding	733400	shares
CY2023Q1	us-gaap	Other General Expense OtherGeneralExpense	10000	usd
CY2023Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
CY2022Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
CY2023Q1	cffe	Working Capital Loan WorkingCapitalLoan	500000	usd
CY2022Q3	cffe	Second Extension Loan SecondExtensionLoan	976832	usd
CY2022Q3	cffe	Public Share Per Share PublicSharePerShare	0.33
CY2023Q2	cffe	Third Extension Loan ThirdExtensionLoan	344781	usd
CY2023Q1	cffe	Face Amounts Loans FaceAmountsLoans	9121000	usd
CY2022Q4	cffe	Face Amounts Loans FaceAmountsLoans	8500000	usd
CY2023Q1	cffe	Aggregate Converted Basis Percentage AggregateConvertedBasisPercentage	0.20	pure
CY2021Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a 1.1-for-1 stock split
CY2023Q1	cffe	Public Warrants Term PublicWarrantsTerm	P5Y
CY2023Q1	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	●in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days’ prior written notice of redemption; ● if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.01
CY2023Q1	us-gaap	Share Price SharePrice	18
CY2023Q1	cffe	Fps Commitment FPSCommitment	10000000	usd
CY2023Q1	us-gaap	Commitments Fair Value Disclosure CommitmentsFairValueDisclosure	10000000	usd
CY2023Q1	cffe	Business Combination BusinessCombination	0.80	pure
CY2022	cffe	Business Combination BusinessCombination	0.80	pure
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CF Acquisition Corp. VIII
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent		usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q1	cffe	Share Conversion1 ShareConversion1		usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts		usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect		usd
CY2022Q1	cffe	Prepaid Expenses Paid With Payables To Related Party PrepaidExpensesPaidWithPayablesToRelatedParty		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001839530

Files In Submission

Name	View Source	Status
0001213900-23-039788-index-headers.html	Edgar Link	pending
0001213900-23-039788-index.html	Edgar Link	pending
0001213900-23-039788.txt	Edgar Link	pending
0001213900-23-039788-xbrl.zip	Edgar Link	pending
cffe-20230331.xsd	Edgar Link	pending
f10q0323ex10-1_cfacq8.htm	Edgar Link	pending
f10q0323ex31-1_cfacq8.htm	Edgar Link	pending
f10q0323ex31-2_cfacq8.htm	Edgar Link	pending
f10q0323ex32-1_cfacq8.htm	Edgar Link	pending
f10q0323ex32-2_cfacq8.htm	Edgar Link	pending
f10q0323_cfacq8.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
cffe-20230331_cal.xml	Edgar Link	unprocessable
cffe-20230331_def.xml	Edgar Link	unprocessable
cffe-20230331_pre.xml	Edgar Link	unprocessable
cffe-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_cfacq8_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XBP
XBP Europe Holdings Inc Stock $xbp

2023 Q1 Form 10-Q Financial Statement

#000121390023039788 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XBP XBP Europe Holdings Inc Stock $xbp

2023 Q1 Form 10-Q Financial Statement

#000121390023039788 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XBP
XBP Europe Holdings Inc Stock $xbp